MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

Home・Aandelen Lijst・Clearside Biomedical Inc

Clearside Biomedical Inc

Open

4.17 2.21

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.08

Max

4.22

Belangrijke statistieken
By Trading Economics
Inkomsten	3.7M -4.5M
Verkoop	-1.8M 492K
Winstmarge	-913.618
Werknemers	32
EBITDA	1.2M -3.6M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+797.13% upside

Dividenden
By Dow Jones
Volgende Winsten	11 nov 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	22M
Vorige openingsprijs	1.96
Vorige sluitingsprijs	4.17

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

0.8417 / 0.8939 Steun & Weerstand

Clearside Biomedical Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 okt 2025, 23:30 UTC

Populaire aandelen

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 okt 2025, 21:21 UTC

Winsten

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 okt 2025, 00:00 UTC

Acquisities, Fusies, Overnames

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 okt 2025, 23:40 UTC

Marktinformatie

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 okt 2025, 23:39 UTC

Marktinformatie

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 okt 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 okt 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 okt 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 okt 2025, 23:00 UTC

Marktinformatie

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 okt 2025, 22:54 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Scales's JV Buyout Lauded by Bull -- Market Talk

2 okt 2025, 22:54 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Global Forex and Fixed Income Roundup: Market Talk

2 okt 2025, 22:46 UTC

Marktinformatie

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 okt 2025, 22:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

2 okt 2025, 21:17 UTC

Acquisities, Fusies, Overnames

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 okt 2025, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Energy & Utilities Roundup: Market Talk

2 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

2 okt 2025, 20:49 UTC

Acquisities, Fusies, Overnames

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 okt 2025, 20:00 UTC

Acquisities, Fusies, Overnames

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 okt 2025, 19:20 UTC

Marktinformatie

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 okt 2025, 19:10 UTC

Marktinformatie

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 okt 2025, 19:04 UTC

Marktinformatie

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 okt 2025, 18:45 UTC

Acquisities, Fusies, Overnames

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 okt 2025, 18:45 UTC

Acquisities, Fusies, Overnames

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 okt 2025, 18:44 UTC

Acquisities, Fusies, Overnames

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 okt 2025, 18:44 UTC

Acquisities, Fusies, Overnames

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 okt 2025, 18:44 UTC

Acquisities, Fusies, Overnames

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 okt 2025, 18:43 UTC

Acquisities, Fusies, Overnames

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Peer Vergelijking

Prijswijziging

Clearside Biomedical Inc Prognose

Koersdoel

By TipRanks

797.13% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 37.5 USD 797.13%

Hoogste 45 USD

Laagste 30 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Clearside Biomedical Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Clearside Biomedical Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.8417 / 0.8939Steun & Weerstand

The bullish and bearish events are balanced.

Recent bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.